Financings in Brief: OrthoLogic
This article was originally published in The Gray Sheet
Executive Summary
OrthoLogic: Files registration statement with the Securities and Exchange Commission for a secondary offering of 2.45 mil. shares, of which 1,749,738 are being offered by the company and 700,262 by selling shareholders. Anticipated proceeds of about $15.4 mil. -- based on an offering price of $9.50 per share -- would go toward working capital, general corporate purposes and R&D. The firm is in preclinicals for its OrthoSound nonthermal ultrasound technology for use in the noninvasive diagnosis and repair of damaged bones, cartilage, ligaments and tendons. Phoenix, Arizona-based OrthoLogic is also working on expanded applications of its primary product, the OrthoLogic 1000 bone growth stimulator ("The Gray Sheet" Sept. 11, In Brief). Approximately 9.2 mil. shares would be outstanding after the offering. Underwriters are Volpe, Welty & Co. and Dain Bosworth...
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.